Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today released its 2024 corporate
responsibility report detailing Twist’s approach to sustainability,
social responsibility and ethics. The report highlights Twist’s
ongoing commitment to advancing sustainable initiatives to best
serve customers, communities and the planet.
“At Twist, we’re always looking to the future and improving what
we do, whether that's delivering new products, providing
development opportunities for our employees, continuing to hold
ourselves to the highest standards of biosecurity or our efforts in
sustainability,” said Emily M. Leproust, Ph.D., CEO and co-founder
of Twist Bioscience. “Last year we quantified the carbon footprint
of manufacturing a single Twist gene compared to approaches that
use a 96-well plate and found the differential to be astounding.
This year we quantified the carbon footprint of our oligo
manufacturing process specific to our NGS target enrichment panels.
For a year’s production of Twist panels, we found that our process
emitted the equivalent CO2 emissions as about 2.4 tanker trucks of
gasoline compared to over 6,000 tanker trucks’ worth of gasoline
for the industry standard 96-well plate approach.1”
Dr. Leproust continued, “Sustainability starts with our
platform. Whether our customers purchase genes and other synbio
products manufactured in our Wilsonville facility or target
enrichment panels manufactured in South San Francisco, by choosing
Twist, they receive excellent products and a remarkable team, and
for no extra cost, embrace sustainable practices, as corporate
responsibility is integrated into our operations.”
An Inherently Sustainable Platform
Twist’s silicon-based synthetic DNA manufacturing platform
offers a more sustainable alternative to legacy methods by
miniaturizing the chemical reaction to synthesizing DNA, using
99.8% less reagents than 96-well plate approaches. Twist quantified
the carbon footprint of manufacturing a single gene using its
silicon chip-based platform compared to approaches that use a
96-well plate. Twist’s approach emits 36 grams (0.036 kilograms) of
carbon dioxide equivalent (CO2e) per gene, compared to up to 23,000
grams (23 kilograms) per gene emitted by 96-well plate
approaches2.
Beyond quantifying the carbon footprint of manufacturing a
single gene, Twist calculated the carbon footprint of its oligo
manufacturing process specific to its NGS target enrichment panels
and found that the chemicals used in Twist's NGS target enrichment
panel production for fiscal 2023 generated 180,000 kg of CO2e
emissions. In contrast, using the industry standard 96-well plate
chemical volumes and approach to manufacture the equivalent number
of NGS target enrichment panels would have generated a massive
470,000,000 kg of CO2e2.
For the first time in its 11-year history, Twist disclosed its
Scope 1 and Scope 2 emissions of 6.27 and 14,315 metric tons of
CO2e, respectively, across its U.S. sites. Disclosing these data
further demonstrates Twist’s commitment to transparency and
environmental stewardship.
Commitment to Ethics and Governance
Twist works with governments as well as other DNA synthesis
providers to develop, promote and evolve a consistent set of
biosecurity best practices. These partnerships align with the
company's dedication to biosecurity and export control screening,
ensuring Twist supports safe, responsible research and that
potentially dangerous DNA sequences are not synthesized or shipped
to unlicensed organizations.
Twist also prioritizes the privacy of its customers and
employees by consistently evaluating and upgrading its system
security. The company has implemented robust cybersecurity and
biosecurity policies, including an International Organization for
Standardization (ISO) certified information security management
system with a recent 2022 revision certification (ISO 27001:2022).
This positions Twist well ahead of the 2025 requirement for all
ISO-certified organizations and reinforces Twist’s commitment to
protecting customer and partner data.
Fostering a Diverse Workforce
Twist is committed to employing a diverse workforce and
fostering a culture of inclusivity. As of the end of fiscal 2023,
56% of Twist’s U.S. organization identified as an individual of
color, with 24% of the U.S. employee base identifying as women of
color. Women play a pivotal role in the company at all levels,
making up 42% of Twist’s executive team and 42% of its total
workforce in fiscal 2023.
Twist’s commitment to diversity in its recruitment efforts
extends to partnerships with local community colleges in
California, Oregon and Massachusetts to help shape the biotech
curriculum and train the next generation of biomanufacturers.
As part of its commitment to employee development, Twist
encourages educational and developmental growth for employees by
offering a year-long leadership program for mid-level managers and
an annual tuition reimbursement of up to $5,250 for all employees.
In the last fiscal year, Twist invested over $220,000 in employee
learning, specialized training, and in providing self-directed
learning opportunities for all employees and leadership looking to
refine or develop their professional skills.
In fiscal 2023, Twist employees volunteered a total of 1,143
hours to numerous causes and organizations, made possible by a
Volunteer Time Off program encouraging employees to participate in
philanthropic initiatives by providing 8 hours of paid time off per
year for volunteer efforts.
To download the full report visit:
https://www.twistbioscience.com/company/corporate-responsibility
1Calculated Twist internal data using Dr. Oligo benchmark
January 2021. Comparison calculated using the EPA Greenhouse Gas
Equivalencies Calculator 2Calculated Twist internal data using Dr.
Oligo benchmark January 2021
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on LinkedIn | X | YouTube | Instagram
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including the execution of Twist’s vision and strategy
with respect to sustainability, diversity, governance, and ethical
commitments and the completion of Twist’s projects that are
currently underway, in development or otherwise under
consideration. Forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
ability to achieve the expected benefits of Twist Bioscience’s
restructuring activities and reduced investments in DNA data
storage; the ability to attract new customers and retain and grow
sales from existing customers; the ability of Twist Bioscience to
achieve sufficient revenue to achieve or maintain positive cash
flow from operations or profitability in any given period will
depend heavily on the success of our existing products and the
development and commercialization of additional products in the
synthetic biology, biologic drug and data storage industries; risks
and uncertainties of rapidly changing technologies and extensive
competition in synthetic biology that could make the products Twist
Bioscience is developing obsolete or non-competitive; uncertainties
of the retention of significant customers; the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits from acquisitions; supply chain and other
disruptions; risks of third party claims alleging infringement of
patents and proprietary rights or seeking to invalidate Twist
Bioscience’s patents or proprietary rights; and the risk that Twist
Bioscience’s proprietary rights may be insufficient to protect its
technologies. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Annual Report on Form 10-K
filed with the SEC on November 21, 2023 and subsequent filings with
the SEC. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Twist Bioscience
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240909630223/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Manager
774-265-5334 ahoulihan@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Twist Bioscience (NASDAQ:TWST)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024